Comparative Pharmacology
Head-to-head clinical analysis: DEMI REGROTON versus HYDRO RESERP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMI REGROTON versus HYDRO RESERP.
DEMI-REGROTON vs HYDRO-RESERP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DEMI-REGROTON is a fixed-dose combination of chlorothiazide (a thiazide diuretic) and reserpine (a Rauwolfia alkaloid). Chlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Reserpine depletes catecholamines (norepinephrine, dopamine, serotonin) from central and peripheral nerve endings by inhibiting vesicular monoamine transporter 2 (VMAT2), leading to reduced sympathetic outflow and vasodilation.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing reabsorption of sodium and chloride and promoting diuresis. Reserpine is a Rauwolfia alkaloid that depletes catecholamines (norepinephrine, dopamine, serotonin) from adrenergic nerve endings and brain, leading to reduced sympathetic outflow and vasodilation.
One tablet orally once daily, each tablet containing 25 mg chlorthalidone and 0.125 mg reserpine.
HYDRO-RESERP contains hydrochlorothiazide (HCTZ) and reserpine. HCTZ: 25-100 mg daily orally; reserpine: 0.125-0.25 mg daily orally. Administer once daily unless intolerable hypotension; then split doses. Avoid doses exceeding HCTZ 100 mg/day and reserpine 0.25 mg/day.
None Documented
None Documented
Terminal elimination half-life is 40-60 hours (mean 48 h), allowing once-daily dosing; steady state reached in 5-7 days
50-100 hours (terminal); prolonged in renal impairment, leading to accumulation on repeated dosing.
Renal: 70% as unchanged drug; biliary/fecal: 30% as metabolites
Renal: 30-40% as unchanged reserpine; biliary/fecal: 60-70% as metabolites.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination